Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

SAN FRAN­CIS­CO — As a high-pro­file fig­ure in the biotech boom that has trans­formed the in­dus­try over the last decade, Alex­is Borisy co-found­ed a slew of star­tups. One of those com­pa­nies is Blue­print Med­i­cines, where he has been on the board since 2011.

A few days ago, Borisy’s biotech reached a mile­stone every up­start yearns for. The FDA ap­proved their first pre­ci­sion can­cer med­i­cine — and the ex­ec­u­tive team im­me­di­ate­ly priced it in the US at a stag­ger­ing $32,000 a month, al­most twice what some an­a­lysts had ex­pect­ed. If it per­forms ac­cord­ing to the US mod­el, that’s far more than any oth­er pay­er will cov­er in the rest of the world — even af­ter any ne­go­ti­at­ed dis­count. And that’s just the lat­est in a long line­up of new drugs from com­pa­nies big and small bid­ding up ever-high­er price tags.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER